The European project ANTI-SUPERBUGS PCP

The antimicrobial resistant organisms (AMRO), also known as superbugs, are invisible and can survive up to three days on certain surfaces. This means they can be transferred whenever an infected person simply touches another, or by contact with an object on which the bugs are thriving, such as a stethoscope or a TV remote. Infections caused by these microorganisms often fail to respond to standard treatment, resulting in prolonged hospital stays, higher healthcare costs, and an increased risk of death.
To address this problem in an innovative way, the ANTI-SUPERBUGS PCP project, led by Dr. Enrique Limón, researcher at Bellvitge Biomedical Research Institute (IDIBELL) was launched last September 1st. The project, which will last for four years, is part of the pre-commercial procurement (PCP) initiatives funded by the European Commission’s H2020 framework program.
"Resistance to antibiotics varies depending on geographic location and is directly proportional to the use and misuse of antibiotics," explains Dr. Enrique Limón. "There are active surveillance systems, implemented in all European states, thanks to which infections by resistant microorganisms have decreased in recent years, but unfortunately the efforts made so far are not enough to eradicate them."
The microbiology services play a fundamental role in the identification and monitoring of "superbugs", but time of diagnosis remains as an unresolved issue that affects all prevention and treatment strategies carried out by the infectious diseases services; that is the main reason behind ANTI-SUPERBUGS PCP. "We want to challenge the industry to develop innovative, smart ICT solutions that detect the presence of resistance microorganisms, give real-time feedback to the user and share the information with the healthcare provider's electronic record systems linking the infection with the place of detection" says Dr. Limón.
Pre-commercial procurement (PCP) is the acquisition of research and development of new innovative solutions before they become available on the market. The support of European Commission to the CPP projects is expanding in its latest Horizon 2020 framework program, with financial incentives such as the PCP Co-Fund actions available for consortia of public procurers working together on joint PCPs within the domain of research and innovation defined under each different program.

抗菌素耐药性生物体（AMRO），亦称超级细菌，无形且能在特定表面存活长达三天。这意味着，它们可在感染者不经意间触摸他人或接触携带这些细菌的物体，如听诊器或电视遥控器时传播。由这些微生物引起的感染往往对标准治疗无反应，导致住院时间延长、医疗保健成本增加以及死亡风险上升。为了以创新的方式解决这一问题，由贝尔维特格生物医学研究学院（IDIBELL）的研究员恩里克·利蒙博士领导的“反超级细菌PCP”项目于上个月1日启动。该项目将持续四年，是欧洲委员会H2020框架计划资助的预商业采购（PCP）倡议的一部分。

“抗菌素的耐药性随地理位置而异，并直接与抗菌素的滥用程度成正比，”恩里克·利蒙博士解释道。“所有欧洲国家都实施了积极的监测系统，这得益于近年来耐药微生物引起的感染有所下降，但遗憾的是，迄今为止的努力尚不足以根除它们。”

微生物学服务在“超级细菌”的识别和监测中扮演着至关重要的角色，但诊断时间仍然是一个未解决的问题，它影响着所有传染病服务部门实施的预防和治疗策略；这正是“反超级细菌PCP”项目的主要原因。“我们希望挑战行业开发创新、智能的信息通信技术（ICT）解决方案，以检测耐药微生物的存在，向用户提供实时反馈，并将信息与医疗保健提供者的电子病历系统相连接，将感染与检测地点联系起来，”利蒙博士说。

预商业采购（PCP）是在新产品创新解决方案上市之前对其进行研究和开发的过程。欧洲委员会对其Horizon 2020框架计划下的PCP项目支持正在扩大，为公共采购商联合体提供了诸如PCP共同基金行动等财政激励措施，这些联合体在各自计划定义的研究和创新领域内共同进行联合PCP。”
}